Image

    Update: Baricitinib for Alopecia Areata

    January 2025 in “ Geneesmiddelenbulletin
    EP Schwarz
    Studysummary This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ema.europa.eu →
    Discuss this study in the Community →

    Related research 1

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019